Mutations in 'Ras' genes known to drive around 25% of human cancers, can protect the cancer cells from the immune system. These genes can suppress the immune system by increasing 'PD-L1' protein level. The findings of this study are further discussed in Immunity journal.
The research shows that mutated Ras genes can suppress the immune system around tumors by increasing levels of a protein called 'PD-L1'. Small amounts of PD-L1 exist naturally in the body to prevent the immune system from attacking healthy cells, but cancer cells can exploit this to protect themselves.
"Understanding how different mutations protect cancer cells from the immune system will help us to offer patients more precise and effective treatments," explains Dr. Matthew Coelho, first author of the paper from the Francis Crick Institute. "Antibodies that target PD-L1 proteins are currently used in the clinic, and they work very well in around a fifth of lung cancer patients. At the moment, doctors can measure PD-L1 levels to help determine which patients might respond best, but this only gives you half of the story".
By revealing the causal link between Ras and PD-L1 levels, and the mechanisms behind it, the new study offers new possibilities for combination therapies using different drugs. As part of the study, mice with Ras mutant cancers were given compounds to counteract the effects of Ras signaling on PD-L1 expression. Their tumors were attacked by the immune system, slowing tumor growth.
"Our study highlights the fundamental role that Ras mutations play throughout the different stages of cancer," explains senior author Professor Julian Downward, Group Leader at the Francis Crick Institute and Head of the Lung Cancer Group at the ICR.
"We already knew that they played a key role in starting around a quarter of all human cancers, causing cancer cells to grow, multiply and spread. We now know that they also help to protect the cancer cells from our immune systems, making them more difficult to treat. Understanding the mechanisms behind this will help us to develop better treatments in future, for example boosting immunotherapy approaches with drugs that disrupt cancer's defenses." said Professor Julian Downward.